CX 8998

Drug Profile

CX 8998

Alternative Names: CX8998

Latest Information Update: 30 Jan 2017

Price : $50

At a glance

  • Originator Cavion
  • Class Small molecules
  • Mechanism of Action T type calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Essential tremor

Most Recent Events

  • 06 Jan 2017 Phase-I clinical trials in Essential tremor (unspecified route) before January 2017 (Cavion's pipeline, January 2017)
  • 06 Jan 2017 Cavion plans a phase II trial for Essential tremor
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top